Could Aimmune Therapeutics Inc (NASDAQ:AIMT) Skyrocket? The Stock Had Too Little Sellers

October 2, 2018 - By Vivian Park

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) registered a decrease of 4.48% in short interest. AIMT’s total short interest was 5.29M shares in October as published by FINRA. Its down 4.48% from 5.54 million shares, reported previously. With 327,300 shares average volume, it will take short sellers 16 days to cover their AIMT’s short positions. The short interest to Aimmune Therapeutics Inc’s float is 13.96%.

The stock decreased 2.16% or $0.59 during the last trading session, reaching $26.69. About 280,669 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 24.44% since October 2, 2017 and is uptrending. It has outperformed by 8.82% the S&P500.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.56 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

Another recent and important Aimmune Therapeutics, Inc. (NASDAQ:AIMT) news was published by Seekingalpha.com which published an article titled: “Aimmune: To Capture The Vast Food Allergy Market” on September 24, 2018.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>